| SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques NC Dalvie, LH Tostanoski, SA Rodriguez-Aponte, K Kaur, S Bajoria, ... Science advances 8 (11), eabl6015, 2022 | 29 | 2022 |
| Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants S Bajoria, K Kaur, OS Kumru, G Van Slyke, J Doering, H Novak, ... Human vaccines & immunotherapeutics 18 (5), 2079346, 2022 | 14 | 2022 |
| A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates NC Dalvie, LH Tostanoski, SA Rodriguez-Aponte, K Kaur, S Bajoria, ... bioRxiv, 2021 | 13 | 2021 |
| Prophylactic Activity of Orally Administered FliD-Reactive Monoclonal SIgA Against Campylobacter Infection L Perruzza, S Jaconi, G Lombardo, D Pinna, F Strati, D Morone, ... Frontiers in immunology 11, 1011, 2020 | 7 | 2020 |
| Nanoalum Formulations Containing Aluminum Hydroxide and CpG 1018TM Adjuvants: The Effect on Stability and Immunogenicity of a Recombinant SARS-CoV-2 … S Bajoria, OS Kumru, J Doering, K Berman, GV Slyke, A Prigodich, ... Vaccines 11 (6), 1030, 2023 | 4 | 2023 |
| Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD) OS Kumru, S Bajoria, K Kaur, JM Hickey, G Van Slyke, J Doering, ... Human Vaccines & Immunotherapeutics 19 (2), 2264594, 2023 | 3 | 2023 |
| Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants SA Rodriguez-Aponte, NC Dalvie, TY Wong, RS Johnston, CA Naranjo, ... Vaccine 41 (5), 1108-1118, 2023 | 3 | 2023 |
| Minimal purification method enables developability assessment of recombinant proteins SA Rodriguez‐Aponte, CA Naranjo, RS Johnston, NC Dalvie, LE Crowell, ... Biotechnology and Bioengineering 121 (8), 2423-2434, 2024 | 2 | 2024 |
| Formulation studies to develop low-cost, orally-delivered secretory IgA monoclonal antibodies for passive immunization against enterotoxigenic Escherichia coli S Bajoria, LR Antunez, OS Kumru, M Klempner, Y Wang, LA Cavacini, ... Journal of Pharmaceutical Sciences 112 (7), 1832-1844, 2023 | 1 | 2023 |
| KU ScholarWorks S Bajoria, OS Kumru, J Doering, A Sergio, H Kleanthous, JC Love, ... | | 2023 |
| In Vitro Stability and in Vivo Performance Considerations to Develop Low-Cost Recombinant Protein Formulations for Passive and Active Immunization S Bajoria University of Kansas, 2023 | | 2023 |
Ozan KumruUniversity of Kansas在 ku.edu 的电子邮件经过验证
